You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,223,584


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,223,584
Title:Recombinant rabies vaccine and methods of preparation and use
Abstract: Live rabies virus vaccines comprising a recombinant rabies virus genome which overexpresses the rabies virus G protein increase apoptotic activity in infected cells, and enhance the generation of anti-rabies immunity in a subject.
Inventor(s): Dietzschold; Bernhard (Newton Square, PA), Hooper; D. Craig (Medford, NJ), Schnell; Matthias J. (Harleysville, PA)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Application Number:10/268,197
Patent Claims:1. A live attenuated rabies vaccine comprising a recombinant rabies virus genome, wherein the recombinant rabies genome comprises at least two rabies G protein genes.

2. The rabies vaccine of claim 1, wherein the rabies virus genome comprises two G protein genes.

3. The rabies vaccine of claim 1, wherein the at least two G protein genes are identical.

4. The rabies vaccine of claim 1, wherein at least one of the at least two G protein genes are from said attenuated rabies virus strains selected from the group consisting of; ERA; SAD B19; SPBN; SN-10; SN10-333; LEP; and SAD.

5. The rabies vaccine of claim 1, wherein the recombinant rabies genome is SPBNGA-GA (SEQ ID NO: 3).

6. A method of producing a live rabies virus vaccine, comprising the steps of: (1) inserting one or more G protein genes into a rabies virus genome which already contains a G protein gene, to produce a recombinant rabies virus genome; (2) constructing an expression vector from the recombinant rabies virus genome; (3) transfecting a cell with the expression vector and recovering infectious recombinant rabies virus for use as a live rabies virus vaccine.

7. The method of claim 6, wherein the recombinant rabies virus genome comprises two G protein genes.

8. The method of claim 6, wherein the G protein genes are identical.

9. The method of claim 6, wherein at least one of the G protein genes derive from rabies virus strains selected from the group consisting of; ERA; SAD B19; SPBN; SN-10; SN10-333; LEP; and SAD.

10. The method of claim 6, wherein the recombinant rabies genome is SPBNGA-GA (SEQ ID NO: 3).

11. A method of vaccinating a subject against rabies, comprising administering an effective amount of the live attenuated rabies vaccine according to claim 1 to the subject, such that cells of the subject are infected with the live attenuated rabies vaccine and the live attenuated rabies vaccine induces overexpression of G protein in the infected cells, wherein an anti-rabies immune response is produced in the subject.

12. The method of claim 11, wherein the subject is a human.

13. The method of claim 11, wherein the subject is a non-human animal.

14. The method of claim 13, wherein the non-human animal is selected from the group consisting of cats; dogs; rats; mice; bats; foxes; raccoons; squirrels; opossum; coyotes; and wolves.

15. The method of claim 11, wherein the rabies vaccines is administered enterally.

16. The method of claim 15, wherein the enteral administration comprises oral administration.

17. The method of claim 16, wherein the oral administration comprises administration through food-baits designed to vaccinate wild animal populations.

18. The method of claim 11, wherein the live attenuated rabies vaccine is administered parenterally.

19. The method of claim 18, wherein the parenteral administration is selected from the group consisting of intramuscular; intra-peritoneal; intra-cranial; subcutaneous; or through a break in the skin.

20. The method of claim 11, wherein the recombinant rabies virus genome comprises two G protein genes.

21. The method of claim 11, wherein the G protein genes are identical.

22. The method of claim 11, wherein at least one of the at least two G protein genes are from attenuated rabies virus strains selected from the group consisting of; ERA; SAD B19; SPBN; SN-10; SN10-333; PM; LEP; and SAD.

23. The method of claim 11, wherein the recombinant rabies genome is SPBNGA-GA.

24. A pharmaceutical composition comprising the live rabies vaccine of claim 1 and a pharmaceutically acceptable carrier or excipient.

25. The pharmaceutical composition of claim 24, wherein the recombinant rabies genome comprises two G protein genes.

26. The pharmaceutical composition of claim 24, wherein the recombinant rabies virus genome is SPBNGA-GA (SEQ ID NO: 3).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.